Newcastle University
- Country
- 🇬🇧United Kingdom
- Ownership
- Private
- Established
- 1963-08-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.ncl.ac.uk
Clinical Trials
60
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (42 trials with phase data)• Click on a phase to view related trials
In This Study, we Are Testing Whether Combining Two Interventions, in the Early Stages of Tinnitus, is More Effective in Quieting Tinnitus Than Using One Treatment Alone in the Later Stages of Tinnitus
- Conditions
- TinnitusAcute
- First Posted Date
- 2025-08-17
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Newcastle University
- Target Recruit Count
- 80
- Registration Number
- NCT07128004
The Effect of Huel on Markers of Inflammation
- Conditions
- 4 Weeks Supplementation of Huel Ready to Eat Foods
- First Posted Date
- 2025-07-03
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Newcastle University
- Target Recruit Count
- 30
- Registration Number
- NCT07049874
- Locations
- 🇬🇧
Faculty of Medical Sciences, Newcastle Upon Tyne, Tyne and wear, United Kingdom
Patient Engagement Investigation of NMS Assist
- Conditions
- Parkinson Disease
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Newcastle University
- Target Recruit Count
- 30
- Registration Number
- NCT07038486
Bioavailability Trial
- Conditions
- Absorption, Metabolism and Excretion in Healthy VolunteersBioavailability and AUC
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Newcastle University
- Target Recruit Count
- 8
- Registration Number
- NCT06686004
- Locations
- 🇬🇧
Nutrtition Suite, DMBB Newcastle University, Newcastle Upon-Tyne, Tyne and Wear, United Kingdom
Neuromuscular Fatigability in Individuals With Heart Failure
- Conditions
- Heart Failure With Reduced Ejection Fraction
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Newcastle University
- Target Recruit Count
- 28
- Registration Number
- NCT06551012
- Prev
- 1
- 2
- 3
- 4
- 5
- 12
- Next
News
Eight Healthy Babies Born in Britain Using Three-Person DNA Technique to Prevent Mitochondrial Disease
Eight healthy babies were born in Britain using an experimental technique that combines DNA from three people to prevent mothers from passing devastating mitochondrial diseases to their children.
Linear Diagnostics Secures £1M to Advance 5-Minute STI Diagnostic Test
Linear Diagnostics has received £1 million in NIHR funding to develop a rapid diagnostic test that can detect sexually transmitted infections in as little as five minutes using their Exponential Amplification technology.
Newcastle University Researchers Identify Novel CD30-Targeting Combination Therapy to Overcome Immune Checkpoint Blockade Resistance in Melanoma
Newcastle University scientists led by Dr. Shoba Amarnath have discovered why over 60% of cancer patients fail to respond to immune checkpoint blockade therapy, identifying regulatory T cells as key drivers of resistance.
Newcastle University Spin-Out FibroFind Acquired by Vespa Capital to Accelerate Fibrosis Drug Development
FibroFind, a Newcastle University spin-out specializing in fibrotic disease drug development, has been acquired by private equity firm Vespa Capital to accelerate international growth.
Novel 3D Bioprinter Developed to Accelerate Drug Discovery with Enhanced Human-Like Tissue Models
Newcastle University scientists have developed ReJI, a 3D bioprinting technology that creates human-like tissue with 10 times higher cell density than existing methods, potentially improving drug testing accuracy.
University of Birmingham Pioneers Personalized Cancer Treatment Approaches with Novel Technologies
University of Birmingham researchers are revolutionizing cancer diagnosis through innovative MRI and machine learning techniques that can identify pediatric brain tumor types in just ten minutes.